Exceptional Regression of Malignant Pleural Mesothelioma with Pembrolizumab Monotherapy.

Hearon, Bernard F; Redelman, Kyle N; Elhomsy, Georges C; Moore, Dennis F

Hearon, Bernard F; Redelman, Kyle N; Elhomsy, Georges C; Moore, Dennis F.

Afiliación

Hearon BF; Department of Orthopaedics, University of Kansas School of Medicine, Wichita, Kansas, USA.
Redelman KN; Kansas Imaging Consultants, Wichita, Kansas, USA.
Elhomsy GC; Endocrine Division, Department of Internal Medicine, University of Kansas School of Medicine, Wichita, Kansas, USA.
Moore DF; Cancer Center of Kansas, Wichita, Kansas, USA.

Case Rep Oncol ; 13(3): 1483-1489, 2020.

Article en En | MEDLINE | ID: mdl-33442373

Palabras clave

Immune checkpoint inhibitor; Immune-related endocrinopathy; Malignant pleural mesothelioma regression; Pembrolizumab monotherapy; Programmed cell death ligand 1 expression; Therapeutic biomarkers

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Case Rep Oncol Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google